Immunomodulation by Imiquimod in Patients with High-Risk Primary Melanoma

Barnetson, 2004, Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells, Clin Exp Dermatol, 29, 639, 10.1111/j.1365-2230.2004.01614.x Buettiker, 2008, Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients, Arch Dermatol, 144, 943, 10.1001/archderm.144.7.943 Comin-Anduix, 2006, Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays, Clin Cancer Res, 12, 107, 10.1158/1078-0432.CCR-05-0136 Comin-Anduix, 2008, Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma, J Transl Med, 6, 22, 10.1186/1479-5876-6-22 Cotter, 2008, Treatment of lentigo maligna with imiquimod before staged excision, Dermatol Surg, 34, 147, 10.1097/00042728-200802000-00002 Craft, 2005, The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine, J Immunol, 175, 1983, 10.4049/jimmunol.175.3.1983 DeGiorgi, 2009, In vivo characterization of the inflammatory infiltrate and apoptotic status in imiquimod-treated basal cell carcinoma, Int J Dermatol, 48, 312, 10.1111/j.1365-4632.2009.03916.x Erickson, 2010, Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery, Int J Dermatol, 49, 482, 10.1111/j.1365-4632.2010.04423.x Gaspari, 2009, Beyond a decade of 5% imiquimod topical therapy, J Drugs Dermatol, 8, 467 Gibson, 2002, Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod, Cell Immunol, 218, 74, 10.1016/S0008-8749(02)00517-8 Green, 2008, Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma, Br J Dermatol, 159, 606, 10.1111/j.1365-2133.2008.08709.x Hemmi, 2002, Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway, Nat Immunol, 3, 196, 10.1038/ni758 Ito, 2002, Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets, J Exp Med, 195, 1507, 10.1084/jem.20020207 Lee, 2005, Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes, Clin Cancer Res, 11, 107, 10.1158/1078-0432.107.11.1 Ma, 2010, The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice, Cell Mol Immunol, 7, 381, 10.1038/cmi.2010.30 Molenkamp, 2007, Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients, Clin Cancer Res, 13, 2961, 10.1158/1078-0432.CCR-07-0050 Naylor, 2003, Treatment of lentigo maligna with topical imiquimod, Br J Dermatol, 149, 66, 10.1046/j.0366-077X.2003.05637.x Oh, 2008, A functional toll-like receptor 8 variant is associated with HIV disease restriction, J Infect Dis, 198, 701, 10.1086/590431 Ooi, 2006, Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial, Br J Dermatol, 154, 72, 10.1111/j.1365-2133.2005.06932.x Pinzon-Charry, 2005, Dendritic cell dysfunction in cancer: a mechanism for immunosuppression, Immunol Cell Biol, 83, 451, 10.1111/j.1440-1711.2005.01371.x Powell, 2009, Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up, Br J Dermatol, 160, 994, 10.1111/j.1365-2133.2009.09032.x Prins, 2006, The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity, J Immunol, 176, 157, 10.4049/jimmunol.176.1.157 Rajpar, 2006, Imiquimod in the treatment of lentigo maligna, Br J Dermatol, 155, 653, 10.1111/j.1365-2133.2006.07476.x Schott, 2008, Association of TLR7 single nucleotide polymorphisms with chronic HCV-infection and response to interferon-a-based therapy, J Viral Hepat, 15, 71 Shu, 2006, Immune responses in the draining lymph nodes against cancer: implications for immunotherapy, Cancer Metastasis Rev, 25, 233, 10.1007/s10555-006-8503-7 Stanley, 2002, Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential, Clin Exp Dermatol, 27, 571, 10.1046/j.1365-2230.2002.01151.x Takeda, 2004, TLR signaling pathways, Semin Immunol, 16, 3, 10.1016/j.smim.2003.10.003 Torres, 2007, Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream, J Transl Med, 5, 7, 10.1186/1479-5876-5-7 Urosevic, 2005, Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment, J Natl Cancer Inst, 97, 1143, 10.1093/jnci/dji207 Vuylsteke, 2004, Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma, Cancer Res, 64, 8456, 10.1158/0008-5472.CAN-03-3251 Yang, 2004, Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance, Nat Immunol, 5, 508, 10.1038/ni1059